AD Ports Group and Hayat Biotech signed a deal to support Hayat Biotech’s global logistics and distribution efforts through AD Ports Group’s advanced pharma logistics network, which includes its cold & ultra-cold pharma hub based in KIZAD.
Specifically, the partnership will help facilitate Hayat Biotech’s efforts to set up manufacturing centers around the globe and provide logistics solutions to serve its international markets.
The deal encapsulates shipping of strategic construction supplies, including containers, machinery, raw materials, and equipment, to support the construction of Hayat Biotech’s global biopharmaceutical manufacturing facilities.
Once fully completed, the facilities will produce a number of vital biopharmaceutical products, including the Hayat-Vax vaccine, the first indigenously produced COVID-19 vaccine in the UAE and the Arab world.
We are pleased to have signed an MoU with Hayat Biotech to help facilitate development of its biopharmaceutical manufacturing centres around the world, and support its logistics and distribution efforts through our and the HOPE Consortium’s advanced pharma logistics networks. pic.twitter.com/8v3AEdgggO
— AD Ports Group (@ADPortsGroup) July 13, 2022
As part of the collaboration, the distribution will be handled by the HOPE Consortium, an Abu Dhabi-led partnership which operates one of the largest and most complete end-to-end pharma supply chains on the market today.
Last year, Hayat Biotech announced the development of a purpose-built research and development hub for life sciences, biotechnology and vaccine production.
Set up in KIZAD, the facility will be capable of producing over 200 million vaccine doses annually.
AD Ports Group operates one of the largest supply chains in the region supporting multiple industry sectors, including construction and pharma.
